Vannata B, Conconi A, Winkler J, et al. - By analyzing data of 1,113 diffuse large B-cell lymphoma (DLBCL) patients, researchers determined the incidence and clinical characteristics of late relapses in DLBCL. A more favourable risk profile at presentation, characterized by normal lactate dehydrogenase levels, early Ann Arbor stage and low International Prognostic Index, was detected in late relapsing patients vs those relapsing earlier. Rituximab, when used as a component of the front-line therapy, resulted in lowering of the risk of late relapse. Late relapsing patients vs those relapsing early had a significantly better cause-specific survival (CSS) from the time of relapse: 5-year CSS rates were 53% and 31%, respectively. They also noted a trend toward a better overall survival, with 5-year rates following relapse of 47% and 25%, respectively.